Cadila gets USFDA nod for Ribavirin

Cadila Healthcare has recevied US Food and Drug Administration (USFDA) approval for Ribavirin capsule 200 mg.

According to a release issued by Cadila Healthcare to the BSE today, the company plans to launch Ribavirin capsule, an anti-viral drug, in December in the US market.

"The approval for Ribavirin is the latest in a series of developments that mark the company's foray in the US generic market," the release added.